BCRX Q2 2018 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+303.2% YoY

Gross Profit

$12M98.1% margin

Operating Income

-$18M-146.1% margin

Net Income

-$18M-147.6% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+214.2%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$137M

Total Liabilities

$90M

Stockholders' Equity

$46M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$3M	+303.2%
Gross Profit	$12M	$3M	+298.1%
Operating Income	-$18M	-$16M	-17.6%
Net Income	-$18M	-$17M	-9.2%

Revenue Segments

Royalty

$142,000100%